Newland Pharmaceutical Co., Ltd. (SHE:301277)
China
· Delayed Price · Currency is CNY 11.53
0.00 (0.00%)
Apr 29, 2026, 4:00 PM EDT
Newland Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2019 |
| Market Capitalization | 4,521 | 4,623 | 3,873 | 4,163 | 3,850 | - | Upgrade
|
| Market Cap Growth | -14.09% | 19.35% | -6.96% | 8.12% | - | - | Upgrade
|
| Enterprise Value | 3,856 | 3,913 | 3,072 | 3,378 | 3,952 | - | Upgrade
|
| Last Close Price | 11.33 | 11.59 | 9.48 | 10.01 | 9.12 | - | Upgrade
|
| PE Ratio | 44.75 | 38.13 | 22.31 | 26.19 | 29.10 | - | Upgrade
|
| PS Ratio | 6.85 | 6.88 | 5.33 | 6.39 | 6.14 | - | Upgrade
|
| PB Ratio | 2.85 | 2.98 | 2.51 | 2.87 | 2.83 | - | Upgrade
|
| P/TBV Ratio | 2.94 | 3.08 | 2.57 | 2.95 | 2.92 | - | Upgrade
|
| P/FCF Ratio | - | 297.23 | 242.50 | 25.55 | 452.81 | - | Upgrade
|
| P/OCF Ratio | 74.21 | 39.53 | 30.56 | 16.04 | 46.47 | - | Upgrade
|
| EV/Sales Ratio | 5.85 | 5.82 | 4.23 | 5.19 | 6.30 | - | Upgrade
|
| EV/EBITDA Ratio | 24.34 | 22.74 | 14.20 | 17.72 | 23.61 | - | Upgrade
|
| EV/EBIT Ratio | 38.92 | 32.75 | 16.98 | 20.87 | 27.20 | - | Upgrade
|
| EV/FCF Ratio | -1352.98 | 251.61 | 192.33 | 20.73 | 464.84 | - | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | Upgrade
|
| Debt / EBITDA Ratio | 0.01 | 0.03 | 0.01 | 0.01 | 0.03 | 0.80 | Upgrade
|
| Debt / FCF Ratio | - | 0.37 | 0.19 | 0.02 | 0.67 | 5.34 | Upgrade
|
| Net Debt / Equity Ratio | -0.42 | -0.46 | -0.52 | -0.59 | -0.55 | 0.21 | Upgrade
|
| Net Debt / EBITDA Ratio | -4.25 | -4.14 | -3.72 | -4.49 | -4.46 | 0.53 | Upgrade
|
| Net Debt / FCF Ratio | 233.13 | -45.84 | -50.32 | -5.26 | -87.83 | 3.53 | Upgrade
|
| Asset Turnover | 0.36 | 0.37 | 0.42 | 0.41 | 0.57 | 0.86 | Upgrade
|
| Inventory Turnover | 9.33 | 7.62 | 11.50 | 9.30 | 6.12 | 4.81 | Upgrade
|
| Quick Ratio | 5.95 | 5.81 | 5.26 | 7.89 | 7.14 | 1.42 | Upgrade
|
| Current Ratio | 6.35 | 6.26 | 5.51 | 8.29 | 7.61 | 1.82 | Upgrade
|
| Return on Equity (ROE) | 6.23% | 7.76% | 11.56% | 11.19% | 14.92% | 31.91% | Upgrade
|
| Return on Assets (ROA) | 3.38% | 4.16% | 6.61% | 6.44% | 8.25% | 14.32% | Upgrade
|
| Return on Invested Capital (ROIC) | 10.10% | 13.56% | 23.81% | 23.31% | 24.30% | 27.06% | Upgrade
|
| Return on Capital Employed (ROCE) | 6.00% | 7.40% | 11.30% | 11.00% | 10.50% | 30.50% | Upgrade
|
| Earnings Yield | 2.23% | 2.62% | 4.48% | 3.82% | 3.44% | - | Upgrade
|
| FCF Yield | -0.06% | 0.34% | 0.41% | 3.91% | 0.22% | - | Upgrade
|
| Dividend Yield | 1.73% | 1.73% | 4.22% | 2.04% | 1.86% | - | Upgrade
|
| Payout Ratio | 111.16% | 92.39% | 46.08% | 41.94% | 5.12% | 31.92% | Upgrade
|
| Buyback Yield / Dilution | 0.94% | 0.88% | -1.05% | -29.52% | -2.59% | -0.64% | Upgrade
|
| Total Shareholder Return | 2.67% | 2.61% | 3.17% | -27.48% | -0.72% | -0.64% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.